Exhibit 99.1

 

Viveve Reports Second Quarter 2018 Financial Results and Provides Corporate Update

 

-       

Company reports 80% growth in total quarterly revenue year-over-year

-        Multiple clinical and regulatory milestones achieved for Viveve® System

 

ENGLEWOOD, CO -- August 9, 2018 -- Viveve Medical Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today reported financial results for the second quarter ended June 30, 2018. Total revenue for the three months ended June 30, 2018, was $5.5 million, an 80% increase over total revenue for the same quarter in 2017.

 

“The second quarter was extremely positive for Viveve both in terms of total revenue and on the clinical and regulatory fronts. We made significant progress in advancing our global commercialization strategy, accelerated physician demand for our cryogen-cooled monopolar radiofrequency technology platform, and maintained our industry-leading commitment to scientific rigor,” stated Scott Durbin, chief executive officer and director of Viveve Medical. “On the commercial front, we sold 85 systems worldwide, 81% of which were sold in the growing North American market. This follows the realignment and expansion of our direct sales organization in the first quarter of this year. We look forward to further accelerating our commercial growth through our new U.S. capital sales partnership with Aesthetic Management Partners, which we announced in July.”

 

Mr. Durbin continued, “Among our clinical milestones during this period, we reported positive six-month data from the SUI feasibility study. We are also exceeding enrollment targets for the VIVEVE II study and announced no serious adverse events in our 30-day safety data submission. We are well positioned to continue this momentum as we work to gain regulatory approvals for new indications for our technology in the U.S. including improvement of sexual function and treatment of stress urinary incontinence.”

 

Second Quarter 2018 Business Highlights

 

 

Reported $5.5 million in total revenue for the second quarter of 2018.

 

Reached an installed base of 582 systems worldwide with over 23,000 disposable treatment tips sold globally.

 

Announced expansion of U.S. commercial footprint through a partnership with Aesthetic Management Partners, expanding our sales capabilities to meet increasing physician demand.

 

Reported positive six-month interim data from the stress urinary incontinence (SUI) feasibility study. At six months post-treatment, 83% of women experienced improvement in one-hour pad weight test with an overall mean improvement of 73% and clinically meaningful benefit achieved across all quality of life outcome measures.

 

Initiated the VIVEVE II clinical study to assess the safety and effectiveness of the Viveve® System for the improvement of sexual function. Submitted 30-day safety data for the initial 25 subjects to the U.S. Food and Drug Administration (FDA) for review. Recently announced FDA approval to continue enrollment of up to 100 subjects in second stage of the trial.

 

Submitted Investigational Trial Application to Canadian Ministry of Health to conduct LIBERATE-International registration study in SUI.

 

Reached a favorable settlement in the company’s patent infringement litigation with Thermi.

 

Second Quarter 2018 Financial Results

 

Revenue for the second quarter of 2018 totaled $5,525,000 from the sale of 85 systems, 69 of which were sold in the U.S. market through direct sales, and approximately 2,750 treatment tips, compared to total revenue of $3,076,000 for the same period in 2017, an 80% increase for the quarter year-over-year.

 

 

 

 

Gross profit for the second quarter of 2018 was $2,814,000, or 51% of revenue, compared to a gross profit of $1,239,000, or 40% of revenue, for the same period in 2017.

 

Total operating expenses for the second quarter of 2018 were $13,109,000, up from $10,302,000 in the same period in 2017. This increase is attributed to increased costs to support North America commercialization and expansion into new international markets, research and development efforts, and strategies to protect the company’s intellectual property as well as other general corporate expenses.

 

Net loss for the second quarter of 2018 was $11,516,000, or a loss of $0.37 per share, compared to a net loss of $10,425,000, or a loss of $0.54 per share, for the same period in 2017.

 

Cash and cash equivalents were $30.2 million as of June 30, 2018, a decrease of $8.2 million from $38.4 million as of March 31, 2018.

 

Conference Call Information

 

The company will host a live conference call at 5:00 pm ET today. The conference call may be accessed by dialing 1-833-255-2833 (domestic) or 1-412-902-6723 (international) or via live webcast at https://services.choruscall.com/links/vive180809.html. Participants may also pre-register for the conference call at http://dpregister.com/10122036.

 

A recording of the webcast will be posted on the company’s investor relations website following the call at http://ir.viveve.com and will be available online for 90 days.

 

About Viveve

 

Viveve Medical, Inc. is a women's intimate health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System, that delivers the Viveve treatment, incorporates clinically-proven cryogen-cooled, monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate robust neocollagenesis in a single in-office session.

 

International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications from over 55 countries. Viveve received approval of an Investigational Device Exemption (IDE) application from the U.S. Food and Drug Administration (FDA) in March of 2018 to proceed with VIVEVE II, a multicenter, randomized, double-blind, sham-controlled study to assess improvement of sexual function in women following childbirth. Initiation of the trial began in the second quarter of 2018 and if successful, could support a marketing application for a new U.S. commercial indication. Currently, in the United States, the Viveve System is cleared by the FDA for use in general surgical procedures for electrocoagulation and hemostasis. 

 

Viveve is awaiting approval to conduct two independent, multicenter, randomized, registration trials (LIBERATE-International and LIBERATE-U.S.). The results of these studies, if successful, could support marketing applications in the U.S, and around the world, for the improvement of stress urinary incontinence in women.

 

For more information visit Viveve's website at www.viveve.com.

 

 

 

 

Safe Harbor Statement

 

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

 

Viveve is a registered trademark of Viveve, Inc.

 

Investor Relations contacts:

Sarah McCabe

Stern Investor Relations, Inc.

(212) 362-1200

sarah@sternir.com

 

Amato and Partners, LLC

Investor Relations Counsel

admin@amatoandpartners.com

 

Media contact:

Kelly Wakelee

Berry & Company Public Relations

(212) 253-8881

kwakelee@berrypr.com

 

 

 

 

 

VIVEVE MEDICAL, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

 

   

June 30,

   

December 31,

 
   

2018

   

2017

 

ASSETS

               

Current assets:

               

Cash and cash equivalents

  $ 30,213     $ 20,730  

Accounts receivable, net

    7,241       6,213  

Inventory

    4,161       2,390  

Prepaid expenses and other current assets

    3,024       2,741  

Total current assets

    44,639       32,074  

Property and equipment, net

    1,931       1,303  

Investment in limited liability company

    2,093       2,500  

Other assets

    188       202  

Total assets

  $ 48,851     $ 36,079  

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

               

Current liabilities:

               

Accounts payable

  $ 4,867     $ 4,799  

Accrued liabilities

    5,258       4,605  

Total current liabilities

    10,125       9,404  

Note payable, noncurrent portion

    29,724       28,948  

Other noncurrent liabilities

    305       327  

Total liabilities

    40,154       38,679  

Stockholders’ equity (deficit):

               

Common stock and additional paid-in capital

    138,286       102,981  

Accumulated deficit

    (129,589 )     (105,581 )

Total stockholders’ equity (deficit)

    8,697       (2,600 )

Total liabilities and stockholders’ equity (deficit)

  $ 48,851     $ 36,079  

 

 

 

 

 

VIVEVE MEDICAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

(unaudited)

 

   

Three Months Ended

   

Six Months Ended

 
   

June 30,

   

June 30,

 
   

2018

   

2017

   

2018

   

2017

 
                                 

Revenue

  $ 5,525     $ 3,076     $ 9,224     $ 6,117  

Cost of revenue

    2,711       1,837       5,063       3,456  

Gross profit

    2,814       1,239       4,161       2,661  
                                 

Operating expenses:

                               

Research and development

    3,672       3,440       7,428       5,828  

Selling, general and administrative

    9,437       6,862       18,368       12,312  

Total operating expenses

    13,109       10,302       25,796       18,140  

Loss from operations

    (10,295 )     (9,063 )     (21,635 )     (15,479 )

Interest expense, net

    (1,063 )     (1,345 )     (2,133 )     (1,608 )

Other expense, net

    -       (17 )     (10 )     (33 )

Net loss from consolidated companies

    (11,358 )     (10,425 )     (23,778 )     (17,120 )

Loss from minority interest

    (158 )     -       (407 )     -  

Net loss

  $ (11,516 )   $ (10,425 )   $ (24,185 )   $ (17,120 )
                                 
                                 

Net loss per share:

                               

Basic and diluted

  $ (0.37 )   $ (0.54 )   $ (0.85 )   $ (1.10 )
                                 

Weighted average shares used in computing net loss per common share:

                               

Basic and diluted

    31,305,386       19,373,322       28,591,134       15,539,840  

 

 

View differences made from one to another to evaluate Viveve Medical, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Viveve Medical, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account